Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy
The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of wh...
Gespeichert in:
| Veröffentlicht in: | Clinical breast cancer 2017-12, Vol.17 (8), p.644-649 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 649 |
|---|---|
| container_issue | 8 |
| container_start_page | 644 |
| container_title | Clinical breast cancer |
| container_volume | 17 |
| creator | Nogi, Hiroko Uchida, Ken Mimoto, Rei Kamio, Makiko Shioya, Hisashi Toriumi, Yasuo Suzuki, Masafumii Nagasaki, Eijiro Kobayashi, Tadashi Takeyama, Hiroshi |
| description | The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.
Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC.
At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013. The clinicopathological and survival data of patients who underwent SNB after NAC (the NAC group) and those who underwent SNB without NAC (the control group) were compared. Patients with a metastatic sentinel node underwent axillary lymph node dissection.
The number of patients in the NAC and control groups was 183 (15.5%) and 996 (84.5%), respectively. At diagnosis, tumors were significantly larger in the NAC group (P < .0001). Sentinel nodes were identified in almost all patients in both groups (99.5% in the NAC group vs. 99.8% in the control group). They were nonmetastatic in 147 (80.8%) patients in the NAC group and 849 (85.5%) patients in the control group. At the median follow-up time of 51.1 months, 6 patients (0.6%) in the control group had axillary lymph node recurrence compared with no patients in the NAC group.
SNB after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB. |
| doi_str_mv | 10.1016/j.clbc.2017.05.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1908793068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1526820917302215</els_id><sourcerecordid>1908793068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-f411d3f929da18c5dda153e46164ad6c2f30076165f339298be0c205ae6f304d3</originalsourceid><addsrcrecordid>eNp9kM1u1DAURi0Eoj_wAiyQl2wSru3Ek0hs2lFLkUYDEu3a8tg3rUdJHGwnaBa8Ox6msGR17evzfZIPIe8YlAyY_LgvTb8zJQe2KqEuAfgLcs5a0RQgpXyZzzWXRcOhPSMXMe4zIAWD1-SMNxKYaPg5-bXx42Nxj2Ggt77v_c_iYaK-o1tvsdjio05uQXodUMdE13o0GOi3vMQxRXqz6H7WCS1dnKbf886N2P_J0mvnp3igV13KiS16bffzosdc8oSDT08Y9HR4Q151uo_49nlekofbm_v1XbH5-vnL-mpTmAogFV3FmBVdy1urWWNqm0ctsJJMVtpKwzsBsMq3uhMiU80OwXCoNcr8UllxST6ceqfgf8wYkxpcNNj3ekQ_R8VaaFatANlklJ9QE3yMATs1BTfocFAM1FG72qujdnXUrqBW2WoOvX_un3cD2n-Rv54z8OkEYP7l4jCoaLJDg9YFNElZ7_7X_xslR5PB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1908793068</pqid></control><display><type>article</type><title>Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nogi, Hiroko ; Uchida, Ken ; Mimoto, Rei ; Kamio, Makiko ; Shioya, Hisashi ; Toriumi, Yasuo ; Suzuki, Masafumii ; Nagasaki, Eijiro ; Kobayashi, Tadashi ; Takeyama, Hiroshi</creator><creatorcontrib>Nogi, Hiroko ; Uchida, Ken ; Mimoto, Rei ; Kamio, Makiko ; Shioya, Hisashi ; Toriumi, Yasuo ; Suzuki, Masafumii ; Nagasaki, Eijiro ; Kobayashi, Tadashi ; Takeyama, Hiroshi</creatorcontrib><description>The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.
Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC.
At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013. The clinicopathological and survival data of patients who underwent SNB after NAC (the NAC group) and those who underwent SNB without NAC (the control group) were compared. Patients with a metastatic sentinel node underwent axillary lymph node dissection.
The number of patients in the NAC and control groups was 183 (15.5%) and 996 (84.5%), respectively. At diagnosis, tumors were significantly larger in the NAC group (P < .0001). Sentinel nodes were identified in almost all patients in both groups (99.5% in the NAC group vs. 99.8% in the control group). They were nonmetastatic in 147 (80.8%) patients in the NAC group and 849 (85.5%) patients in the control group. At the median follow-up time of 51.1 months, 6 patients (0.6%) in the control group had axillary lymph node recurrence compared with no patients in the NAC group.
SNB after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.</description><identifier>ISSN: 1526-8209</identifier><identifier>EISSN: 1938-0666</identifier><identifier>DOI: 10.1016/j.clbc.2017.05.002</identifier><identifier>PMID: 28601382</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Axilla ; Axillary recurrence-free survival rates ; Biopsy ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Chemotherapy ; Chemotherapy, Adjuvant - methods ; Diagnostic Imaging - methods ; Female ; Follow-Up Studies ; Humans ; Incidence ; Kaplan-Meier Estimate ; Lymph Nodes - diagnostic imaging ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Mastectomy ; Middle Aged ; Neoadjuvant ; Neoadjuvant Therapy - methods ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - prevention & control ; Retrospective Studies ; Sentinel Lymph Node Biopsy ; Sentinel node ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical breast cancer, 2017-12, Vol.17 (8), p.644-649</ispartof><rights>2017 The Authors</rights><rights>Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-f411d3f929da18c5dda153e46164ad6c2f30076165f339298be0c205ae6f304d3</citedby><cites>FETCH-LOGICAL-c400t-f411d3f929da18c5dda153e46164ad6c2f30076165f339298be0c205ae6f304d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1526820917302215$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28601382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nogi, Hiroko</creatorcontrib><creatorcontrib>Uchida, Ken</creatorcontrib><creatorcontrib>Mimoto, Rei</creatorcontrib><creatorcontrib>Kamio, Makiko</creatorcontrib><creatorcontrib>Shioya, Hisashi</creatorcontrib><creatorcontrib>Toriumi, Yasuo</creatorcontrib><creatorcontrib>Suzuki, Masafumii</creatorcontrib><creatorcontrib>Nagasaki, Eijiro</creatorcontrib><creatorcontrib>Kobayashi, Tadashi</creatorcontrib><creatorcontrib>Takeyama, Hiroshi</creatorcontrib><title>Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy</title><title>Clinical breast cancer</title><addtitle>Clin Breast Cancer</addtitle><description>The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.
Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC.
At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013. The clinicopathological and survival data of patients who underwent SNB after NAC (the NAC group) and those who underwent SNB without NAC (the control group) were compared. Patients with a metastatic sentinel node underwent axillary lymph node dissection.
The number of patients in the NAC and control groups was 183 (15.5%) and 996 (84.5%), respectively. At diagnosis, tumors were significantly larger in the NAC group (P < .0001). Sentinel nodes were identified in almost all patients in both groups (99.5% in the NAC group vs. 99.8% in the control group). They were nonmetastatic in 147 (80.8%) patients in the NAC group and 849 (85.5%) patients in the control group. At the median follow-up time of 51.1 months, 6 patients (0.6%) in the control group had axillary lymph node recurrence compared with no patients in the NAC group.
SNB after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Axilla</subject><subject>Axillary recurrence-free survival rates</subject><subject>Biopsy</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Diagnostic Imaging - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymph Nodes - diagnostic imaging</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Mastectomy</subject><subject>Middle Aged</subject><subject>Neoadjuvant</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Retrospective Studies</subject><subject>Sentinel Lymph Node Biopsy</subject><subject>Sentinel node</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1526-8209</issn><issn>1938-0666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1u1DAURi0Eoj_wAiyQl2wSru3Ek0hs2lFLkUYDEu3a8tg3rUdJHGwnaBa8Ox6msGR17evzfZIPIe8YlAyY_LgvTb8zJQe2KqEuAfgLcs5a0RQgpXyZzzWXRcOhPSMXMe4zIAWD1-SMNxKYaPg5-bXx42Nxj2Ggt77v_c_iYaK-o1tvsdjio05uQXodUMdE13o0GOi3vMQxRXqz6H7WCS1dnKbf886N2P_J0mvnp3igV13KiS16bffzosdc8oSDT08Y9HR4Q151uo_49nlekofbm_v1XbH5-vnL-mpTmAogFV3FmBVdy1urWWNqm0ctsJJMVtpKwzsBsMq3uhMiU80OwXCoNcr8UllxST6ceqfgf8wYkxpcNNj3ekQ_R8VaaFatANlklJ9QE3yMATs1BTfocFAM1FG72qujdnXUrqBW2WoOvX_un3cD2n-Rv54z8OkEYP7l4jCoaLJDg9YFNElZ7_7X_xslR5PB</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Nogi, Hiroko</creator><creator>Uchida, Ken</creator><creator>Mimoto, Rei</creator><creator>Kamio, Makiko</creator><creator>Shioya, Hisashi</creator><creator>Toriumi, Yasuo</creator><creator>Suzuki, Masafumii</creator><creator>Nagasaki, Eijiro</creator><creator>Kobayashi, Tadashi</creator><creator>Takeyama, Hiroshi</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy</title><author>Nogi, Hiroko ; Uchida, Ken ; Mimoto, Rei ; Kamio, Makiko ; Shioya, Hisashi ; Toriumi, Yasuo ; Suzuki, Masafumii ; Nagasaki, Eijiro ; Kobayashi, Tadashi ; Takeyama, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-f411d3f929da18c5dda153e46164ad6c2f30076165f339298be0c205ae6f304d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Axilla</topic><topic>Axillary recurrence-free survival rates</topic><topic>Biopsy</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Diagnostic Imaging - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymph Nodes - diagnostic imaging</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Mastectomy</topic><topic>Middle Aged</topic><topic>Neoadjuvant</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Retrospective Studies</topic><topic>Sentinel Lymph Node Biopsy</topic><topic>Sentinel node</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nogi, Hiroko</creatorcontrib><creatorcontrib>Uchida, Ken</creatorcontrib><creatorcontrib>Mimoto, Rei</creatorcontrib><creatorcontrib>Kamio, Makiko</creatorcontrib><creatorcontrib>Shioya, Hisashi</creatorcontrib><creatorcontrib>Toriumi, Yasuo</creatorcontrib><creatorcontrib>Suzuki, Masafumii</creatorcontrib><creatorcontrib>Nagasaki, Eijiro</creatorcontrib><creatorcontrib>Kobayashi, Tadashi</creatorcontrib><creatorcontrib>Takeyama, Hiroshi</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nogi, Hiroko</au><au>Uchida, Ken</au><au>Mimoto, Rei</au><au>Kamio, Makiko</au><au>Shioya, Hisashi</au><au>Toriumi, Yasuo</au><au>Suzuki, Masafumii</au><au>Nagasaki, Eijiro</au><au>Kobayashi, Tadashi</au><au>Takeyama, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy</atitle><jtitle>Clinical breast cancer</jtitle><addtitle>Clin Breast Cancer</addtitle><date>2017-12</date><risdate>2017</risdate><volume>17</volume><issue>8</issue><spage>644</spage><epage>649</epage><pages>644-649</pages><issn>1526-8209</issn><eissn>1938-0666</eissn><abstract>The purpose of this study was to assess the usefulness of sentinel node biopsy (SNB) after neoadjuvant chemotherapy (NAC) in patients with clinically node-negative breast cancer. SNB after NAC was as accurate as SNB without NAC. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.
Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC.
At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013. The clinicopathological and survival data of patients who underwent SNB after NAC (the NAC group) and those who underwent SNB without NAC (the control group) were compared. Patients with a metastatic sentinel node underwent axillary lymph node dissection.
The number of patients in the NAC and control groups was 183 (15.5%) and 996 (84.5%), respectively. At diagnosis, tumors were significantly larger in the NAC group (P < .0001). Sentinel nodes were identified in almost all patients in both groups (99.5% in the NAC group vs. 99.8% in the control group). They were nonmetastatic in 147 (80.8%) patients in the NAC group and 849 (85.5%) patients in the control group. At the median follow-up time of 51.1 months, 6 patients (0.6%) in the control group had axillary lymph node recurrence compared with no patients in the NAC group.
SNB after NAC was as accurate as SNB without NAC in patients with clinically node-negative breast cancer. Axillary recurrence-free survival rates were excellent regardless of whether NAC was performed before SNB.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28601382</pmid><doi>10.1016/j.clbc.2017.05.002</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-8209 |
| ispartof | Clinical breast cancer, 2017-12, Vol.17 (8), p.644-649 |
| issn | 1526-8209 1938-0666 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1908793068 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Axilla Axillary recurrence-free survival rates Biopsy Breast Neoplasms - diagnostic imaging Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Chemotherapy Chemotherapy, Adjuvant - methods Diagnostic Imaging - methods Female Follow-Up Studies Humans Incidence Kaplan-Meier Estimate Lymph Nodes - diagnostic imaging Lymph Nodes - pathology Lymphatic Metastasis Mastectomy Middle Aged Neoadjuvant Neoadjuvant Therapy - methods Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - prevention & control Retrospective Studies Sentinel Lymph Node Biopsy Sentinel node Treatment Outcome Young Adult |
| title | Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A13%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Follow-Up%20of%20Node-Negative%20Breast%20Cancer%20Patients%20Evaluated%20via%20Sentinel%20Node%20Biopsy%20After%20Neoadjuvant%20Chemotherapy&rft.jtitle=Clinical%20breast%20cancer&rft.au=Nogi,%20Hiroko&rft.date=2017-12&rft.volume=17&rft.issue=8&rft.spage=644&rft.epage=649&rft.pages=644-649&rft.issn=1526-8209&rft.eissn=1938-0666&rft_id=info:doi/10.1016/j.clbc.2017.05.002&rft_dat=%3Cproquest_cross%3E1908793068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1908793068&rft_id=info:pmid/28601382&rft_els_id=S1526820917302215&rfr_iscdi=true |